Drug or treatment

Mosunetuzumab clinical trials

• 26Clinical trials
• 21Countries

Newest trials

All recruiting trials (26)

• Mosunetuzumab for people with systemic lupus erythematosus

  This study tests mosunetuzumab in people with systemic lupus erythematosus, with or without active lupus nephritis.

  Recruiting at 24 sites Phase 2 Hoffmann-La Roche · CABA, Buenos Aires and 23 other locations · NCT07598396

• Phase 2 test of mosunetuzumab for CLL patients with detectable MRD

  This study tests whether adding mosunetuzumab to ongoing BTKi therapy can eliminate detectable minimal residual disease in adults with chronic lymphocytic leukemia who still have MRD after BTKi treatment.

  Recruiting Phase 2 M.D. Anderson Cancer Center · Houston, Texas · NCT07566364

• Mosunetuzumab and Zeprumetostat in Follicular Lymphoma

  This study tests whether a combination of Mosunetuzumab and Zeprumetostat can help adults with follicular lymphoma.

  Recruiting Phase 2 Institute of Hematology & Blood Diseases Hospital, China · Tianjin, Tianjin Municipality and 1 other locations · NCT07555470

• Mosunetuzumab for adults with relapsed/refractory follicular lymphoma after at least two prior therapies (compassionate use)

  This project will see if the antibody drug mosunetuzumab helps adults with follicular lymphoma that has come back or stopped responding after at least two prior treatments when given through a compassionate use program.

  Recruiting IRCCS San Raffaele · Milan · NCT07278921

• Mosunetuzumab by subcutaneous injection as first-line therapy for low tumor burden follicular lymphoma

  This trial tests whether subcutaneous mosunetuzumab can be safely and effectively used as initial treatment for adults with newly diagnosed follicular lymphoma with low tumor burden.

  Recruiting at 4 sites Phase 2 Tel-Aviv Sourasky Medical Center · Haifa and 3 other locations · NCT07191249

• Mosunetuzumab to clear minimal residual disease in CLL and SLL.

  This trial will try mosunetuzumab, alone or with a BTK inhibitor, to clear minimal residual disease in people with chronic lymphocytic leukemia or small lymphocytic lymphoma.

  Recruiting at 2 sites Phase 1/2 Dana-Farber Cancer Institute · Boston, Massachusetts and 1 other locations · NCT07052695

• Pirtobrutinib plus Mosunetuzumab for relapsed or refractory grade 1–3a follicular lymphoma

  This trial tests whether giving pirtobrutinib together with mosunetuzumab can better treat adults with relapsed or refractory grade 1–3a follicular lymphoma.

  Recruiting Phase 2 University of Washington · Seattle, Washington · NCT06948786

• Using Mosunetuzumab with CHOP to treat Richter's Syndrome

  This study is testing if a new treatment combining Mosunetuzumab with CHOP chemotherapy can help people with Richter's Syndrome who haven't had treatment before.

  Recruiting at 9 sites Phase 2 GELLC (Grupo Español de Leucemia Linfocítica Crónica) · Barcelona, Barcelona and 15 other locations · NCT06926205

• Mosunetuzumab consolidation for older DLBCL patients with detectable ctDNA after pola‑R‑mini‑CHP

  This trial will try mosunetuzumab in older people with DLBCL who have detectable ctDNA after finishing pola‑R‑mini‑CHP to see if it clears leftover cancer DNA and lowers the chance of relapse.

  Recruiting Phase 2 University of Rochester · Rochester, New York · NCT06828991

• Mosunetuzumab and Polatuzumab Vedotin with split-dose CHP in older adults with DLBCL

  This phase 2 study tests whether adding Mosunetuzumab subcutaneous and Polatuzumab Vedotin to a split-dose CHP chemotherapy regimen helps elderly, newly diagnosed DLBCL patients who are frail or unfit.

  Recruiting Phase 2 Medical College of Wisconsin · Milwaukee, Wisconsin · NCT06594939

• Testing Mosunetuzumab for Newly Diagnosed Extranodal Marginal Zone Lymphoma

  This study is testing a new medication called Mosunetuzumab to see if it can help people with newly diagnosed Extranodal Marginal Zone Lymphoma feel better compared to standard treatments.

  Recruiting Phase 2 University of Miami · Miami, Florida · NCT06569680

• Combining two drugs for patients with relapsed marginal zone lymphoma

  This study is testing a combination of two drugs, mosunetuzumab and zanubrutinib, to see if they can help people with relapsed marginal zone lymphoma feel better and improve their chances of recovery.

  Recruiting Phase 2 M.D. Anderson Cancer Center · Houston, Texas · NCT06563505

• Treatment for relapsed or refractory follicular lymphoma using two monoclonal antibodies

  This study is testing a combination of two new treatments for people with follicular lymphoma that hasn't responded to previous therapies to see if they can improve their health and survival.

  Recruiting Phase 2 City of Hope Medical Center · Duarte, California and 1 other locations · NCT06453044

• Low dose mosunetuzumab treatment for indolent B-cell lymphoma

  This study is testing a new low-dose treatment called mosunetuzumab to see if it can help people with indolent B-cell lymphoma by slowing down or stopping the growth of their cancer.

  Recruiting Phase 2 University of Washington · Seattle, Washington · NCT06442475

• Comparing two drug treatments for low tumor burden follicular lymphoma

  This study is testing whether rituximab or mosunetuzumab works better for people with low tumor burden follicular lymphoma to see which treatment helps them live longer and feel better.

  Recruiting at 263 sites Phase 3 National Cancer Institute (NCI) · Birmingham, Alabama and 287 other locations · NCT06337318

• Treatment of untreated high grade B cell lymphoma with mosunetuzumab and chemotherapy

  This study is testing if a new treatment combining mosunetuzumab and chemotherapy can help people with untreated high grade B cell lymphoma feel better and achieve a complete response.

  Recruiting Phase 1/2 OHSU Knight Cancer Institute · Portland, Oregon · NCT06249191

• Combining three anti-cancer drugs for treating relapsed or refractory diffuse large B-cell lymphoma

  This study is testing a combination of three cancer drugs to see if they can help people with tough-to-treat diffuse large B-cell lymphoma feel better and respond to treatment.

  Recruiting at 8 sites Phase 1 National Cancer Institute (NCI) · Duarte, California and 7 other locations · NCT06015880

• Comparing Mosunetuzumab-Lenalidomide to other treatments for relapsed or refractory Marginal Zone Lymphoma

  This study is testing if a new combination of Mosunetuzumab and Lenalidomide can help people with relapsed or refractory Marginal Zone Lymphoma feel better compared to other standard treatments they might have already tried.

  Recruiting at 26 sites Phase 3 The Lymphoma Academic Research Organisation · Anderlecht and 47 other locations · NCT06006117

• Comparing two immunotherapy agents for treating a specific type of lymphoma

  This study is testing whether a new immunotherapy called mosunetuzumab works better than the standard treatment rituximab for people with a specific type of lymphoma.

  Recruiting at 34 sites Phase 2 National Cancer Institute (NCI) · Duarte, California and 36 other locations · NCT05886036

• Treatment of early relapse follicular lymphoma with mosunetuzumab

  This study is testing if a new treatment called mosunetuzumab can help adults with follicular lymphoma who have had a relapse within two years feel better and live longer compared to standard treatments.

  Recruiting at 3 sites Phase 2 Oslo University Hospital · Helsinki and 2 other locations · NCT05849857

• Treatment for relapsed or refractory diffuse large B-cell lymphoma

  This study is testing a new combination of two treatments for people with relapsed or hard-to-treat diffuse large B-cell lymphoma to see if it helps them respond better and live longer.

  Recruiting Phase 2 City of Hope Medical Center · Duarte, California · NCT05672251

• Combination treatment for relapsed B-cell lymphoma

  This study is testing a new combination of treatments for people with relapsed B-cell lymphoma to see if it helps them respond better and live longer.

  Recruiting Phase 2 M.D. Anderson Cancer Center · Houston, Texas · NCT05615636

• Treatment with Mosunetuzumab for newly diagnosed Follicular Lymphoma

  This study is testing if a new treatment called mosunetuzumab can help people who have just been diagnosed with follicular lymphoma feel better before they start other treatments.

  Recruiting at 9 sites Phase 2 Memorial Sloan Kettering Cancer Center · Washington D.C., District of Columbia and 8 other locations · NCT05389293

• Combination treatment for aggressive Non-Hodgkin's Lymphoma

  This study is testing a new combination of treatments for people with aggressive Non-Hodgkin's Lymphoma to see if it can help shrink their tumors when other treatments haven't worked.

  Recruiting Phase 2 University of Miami · Miami, Florida · NCT05260957

• Evaluating mosunetuzumab alone and with venetoclax for chronic lymphocytic leukemia

  This study is testing a new treatment called mosunetuzumab, alone and with another drug called venetoclax, to see how well it works for people with chronic lymphocytic leukemia that hasn't responded to other treatments.

  Recruiting at 24 sites Phase 1 Hoffmann-La Roche · Rochester, Minnesota and 30 other locations · NCT05091424

• First-line treatment for follicular and marginal zone lymphoma using mosunetuzumab and lenalidomide

  This study is testing if a new combination of treatments can help adults with untreated follicular or marginal zone lymphoma feel better and improve their response to therapy.

  Recruiting at 2 sites Phase 2 Brown University · New Haven, Connecticut and 2 other locations · NCT04792502

Quick answers

How many clinical trials of Mosunetuzumab are recruiting right now?

26, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.

Where are these trials running?

In 21 countries. The most sites are in United States (19 trials), Italy (4 trials), France (2 trials), Germany (2 trials), China (2 trials). Each study page lists its sites and which ones are recruiting.

What phases are they in?

Phase 2: 19, Phase 3: 2, Phase 1: 2, Phase 1/2: 2. Trials with no phase listed are usually device, behavioural or observational studies.

How do I join one?

Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.

Find the studies that fit you

A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.

Describe your situation →